Fig. 2
From: Breast cancer survivors’ opinion on personalizing endocrine therapy and developing informative tools
Willingness to participate in a potential clinical trial evaluating a drug that would combine endocrine therapy and an active ingredient directed against endocrine therapy-related adverse events.
